Physician profile
Dana Shepherd
NPI 1952926297
$1,174.03
in general payments reported to CMS, 2019-2025
11 companies · $952 in 2025
The $952 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.30 · 2022: $57.59 · 2023: $74.59 · 2024: $51.83 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.58 | 2021-2025 | |
| Ucb, INC. | $196.13 | 2025 | Bimzelx, Cimzia |
| Amgen INC. | $113.13 | 2025 | Otezla, Otezla |
| Organon LLC | $91.69 | 2025 | Hadlima, Renflexis |
| Novartis Pharmaceuticals Corporation | $83.50 | 2025 | |
| Ani Pharmaceuticals, INC. | $65.70 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $32.27 | 2025 | Orencia |
| Glaxosmithkline, LLC. | $31.16 | 2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $27.59 | 2025 | Acthar |
| Pfizer INC. | $24.70 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $14.58 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.